Pharmacyte Biotech (PMCB) Stock
Biotech developing cell therapy for diabetes and cancer. Here's the price, business snapshot, and what's worth knowing about Pharmacyte Biotech in August 2026.
PharmaCyte Biotech Inc (PMCB) is a clinical-stage biotechnology company developing a cellular encapsulation therapy known as "Cell-in-a-Box". The platform is being investigated for use in pancreatic cancer and as a potential treatment approach for diabetes; programmes remain in early clinical stages. With a market capitalisation of roughly $6.65 million, PharmaCyte is a very small, speculative company that can be highly volatile and subject to binary outcomes from trials, regulatory decisions and financing events. Investors should note the likelihood of further capital raises and dilution, limited liquidity in the share register, and the long timelines common to clinical development. This summary is educational and not investment advice; outcomes are uncertain and past performance is not indicative of future results. Prospective investors should research trial data, management background, cash runway and consult a qualified financial adviser about suitability for their individual circumstances.
Sixth Month Growth Performance
Stock Performance Snapshot
Financial Health
Pharmacyte Biotech is showing solid cash flow and book value, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Cell-in-a-Box tech
A distinctive encapsulation approach may enable targeted therapies; scientific progress matters, though clinical success is far from certain.
Clinical catalysts ahead
Trial results, regulatory steps and partnership news can move the stock materially; such events can be binary and unpredictable.
Small-cap considerations
Very low market cap and limited liquidity increase volatility and the risk of dilution; suitable only for risk-tolerant investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
